Design and Discovery of Substituted 1,3,4‐Thiadiazole–1,3,5‐Triazine Hybrids as Human Immunodeficiency Virus‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors with Anti‐SARS‐CoV‐2 and Antibacterial Activities
ChemMedChem · 27.03.2026 · 21 (6)
DOI: 10.1002/cmdc.202501109 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 30.03.2026. Verfasst von Saumya Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Shalom Institute of Health and Allied Sciences, Sam Higginbottom Universit…. Hauptthemen laut MEDLINE: Triazines, Thiadiazoles, Anti-Bacterial Agents, Reverse Transcriptase Inhibitors. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Department of Science & Technology, MUR PNRR Extended, Partnership initiative on Emerging Infectious Diseases, RAS LR 7/07 project antivirale-unica.
Abstract (Originalsprache)
A new series of substituted 1,3,4‐thiadiazole–1,3,5‐triazine hybrids was rationally designed, synthesized, and evaluated for their antiviral and antibacterial potential. The target di‐substituted ( 9a–e ) and tri‐substituted ( 11a–e ) derivatives were obtained via a stepwise nucleophilic substitution strategy from cyanuric chloride and characterized by spectroscopic techniques. Molecular docking studies against human immunodeficiency virus‐1 reverse transcriptase (HIV‐1 RT) revealed that para ‐substituted analogs displayed superior binding within the non‐nucleoside reverse transcriptase inhibitor pocket through key hydrogen bonding, π–π stacking, and electrostatic interactions. In vitro evaluation identified compounds 11a as the most active candidate. Compound 11a exhibited 83.93% inhibition of RT activity at 1 μM, an EC 50 of 72.7 nM, and effective suppression of HIV‐1 replication in CEM–GFP T cells (85.19% p24 inhibition) with a favorable therapeutic index (TI = 471). Both compounds also demonstrated inhibition of SARS‐CoV‐2‐induced cytopathic effects in Vero E6 cells at noncytotoxic concentrations. In addition, several derivatives showed moderate to good antibacterial activity against tested bacterial strains, with SAR analysis highlighting the importance of substituent electronics and positional effects on bioactivity. Overall, this study establishes substituted 1,3,4‐thiadiazole–1,3,5‐triazine hybrids as promising multifunctional scaffolds for antiviral and antibacterial drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Shalom Institute of Health and Allied Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Prayagraj, Uttar Pradesh, Ind…
- National Centre for Cell Science, SP Pune University Campus, Pune, Maharashtra, India.
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India.
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India.
- Laboratorio di Virologia Molecolare, Dipartimento di Scienze della Vita e Dell'Ambiente, Università degli Studi di Cagliari, Cittadella Universitaria di Monserrato, Monserrato, Italy.
ORCID-Profile: Udaya Pratap Singh
Förderung
- Department of Science & Technology
- MUR PNRR Extended, Partnership initiative on Emerging Infectious Diseases
- RAS LR 7/07 project antivirale-unica
Zitieren
APA
Singh, S., Srivastava, K. S., Kumawat, M. K., Bhat, H. R., Corona, A., Tramontano, E., Mitra, D., & Singh, U. P. (2026). Design and Discovery of Substituted 1,3,4‐Thiadiazole–1,3,5‐Triazine Hybrids as Human Immunodeficiency Virus‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors with Anti‐SARS‐CoV‐2 and Antibacterial Activities. ChemMedChem, 21(6). https://doi.org/10.1002/cmdc.202501109
Vancouver
Singh S, Srivastava KS, Kumawat MK, Bhat HR, Corona A, Tramontano E, et al. Design and Discovery of Substituted 1,3,4‐Thiadiazole–1,3,5‐Triazine Hybrids as Human Immunodeficiency Virus‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors with Anti‐SARS‐CoV‐2 and Antibacterial Activities. ChemMedChem. 2026;21(6). doi:10.1002/cmdc.202501109
BibTeX
@article{Singh2026,
author = {Singh, Saumya and Srivastava, Kumar Saurabh and Kumawat, Mukesh Kumar and Bhat, Hans Raj and Corona, Angela and Tramontano, Enzo and Mitra, Debashis and Singh, Udaya Pratap},
title = {Design and Discovery of Substituted 1,3,4‐Thiadiazole–1,3,5‐Triazine Hybrids as Human Immunodeficiency Virus‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors with Anti‐SARS‐CoV‐2 and Antibacterial Activities},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {6},
doi = {10.1002/cmdc.202501109}
}
EUVIMED